[Therapeutic considerations in XXXX of the inner ear].

@entity455 @entity66 @entity101 @entity6 @entity2319 @entity389 @entity299 @entity209 @entity2169 @entity4288
I propose an analogy between @entity455 of the inner ear and those of other organs like brain, @entity299 in which functional and organic alteration can be objectively demonstrated. Symptomatic disturbances of inner ear circulation are monoform in its clinical appearance and the term of 'otangina' is proposed for the functional result. Three types of vascular distribution are discussed for the different regulatory entities, (I) the proximal cerebral vascular type, (II) the predistal innervated regulatory type and the (III) capillary regulatory type. The formal etiology of @entity389 is is developed on the base of @entity455 , i.e. @entity4288 , functional alterations, i.e. @entity66 , and finally change in the microcirculation by alterations of the rheology of the blood. @entity101 is portrayed as a main example for cardiovascular risk factors with respect to @entity389 but @entity6 , cigarette smoking and other @entity209 leading to vascular disturbances have to be considered. From these considerations I have developed a basic program for the diagnosis of vascular metabolic risk factors which should be realized before any treatment is advocated. I have critically evaluated the benefit and possible hazardous effects of so called 'vasoactive' and 'cephalotropic' drugs. For most inner ear circulatory disease such therapy is contraindicated. The models of drug treatment of acute @entity2319 and the chronic or persistent inner @entity2169 should be evaluated in prospective studies.
